Uncertain how to put money to work in a market that continues to flirt with all-time highs? Jim Cramer has a few ideas. Ten of them.» Read More
*S&P 500 pulls back after hitting intraday record. NEW YORK, June 24- U.S. stocks fell on Tuesday as early enthusiasm from economic data faded and concerns about the violence in Iraq gave investors a reason to sell and book some profits, driving the Dow to its biggest drop in over a month. On Tuesday, the Dow suffered its biggest drop since May 20.
NEW YORK, June 24- U.S. stocks turned lower on Tuesday after stronger-than-expected data lifted them to a fresh record earlier in the day, while the sterling tumbled after the Bank of England governor said spare capacity would need to be used up before a rate rise is needed.
*S&P 500 pulls back a bit after hitting intraday record. NEW YORK, June 24- U.S. stocks mostly slipped on Tuesday as earlier gains from economic data faded, but the Nasdaq advanced as a result of gains in biotech shares.
A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.
*S&P 500 hits intraday record, continues recent strength. NEW YORK, June 24- U.S. stocks rose on Tuesday, boosted by some strong data while the Nasdaq outperformed thanks to gains in technology and biotech shares. Consumer confidence hit its highest level since January 2008 in June, while new home sales jumped 18.6 percent to a six-year high in May.
Take a look at some of Tuesday's midday movers.
*Consumer confidence at highest since Jan 2008. NEW YORK, June 24- U.S. stocks were little changed on Tuesday as some strong data wasn't enough to solidly lift indexes in the wake of a recent rally, though the Nasdaq index was boosted by gains in technology and biotech shares.
NEW YORK, June 24- U.S. stock index futures pointed to a flat open on Tuesday, suggesting investors continued to search for direction following a sharp rally that took indexes to records last week.
June 24- A combination of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco and its experimental lumacaftor succeeded in improving lung function in a pair of closely watched late-stage trials of patients with the most common genetic mutation associated with the rare lung disease.
Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
*Hewlett-Packard's revenue misses Wall St estimates. Among momentum names, noted for high growth and perceptions of excessive valuation, Vertex Pharmaceuticals shares shot up 6 percent to $71.18, while Alexion Pharmaceuticals rose 2.5 percent to $160.48.
May 1- Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, sending its shares up nearly 8 percent.
May 1- Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco with an experimental compound was shown to improve lung function in a mid-stage trial, and its shares rose 10 percent after the news.
Check out which companies are making headlines after the bell Thursday: Expedia, Kraft, OpenTable
Any rebound in the market is likely to be short-lived since it needs a catalyst to sustain gains, and the start of earnings season may disappoint.
Familiar names such as Netflix, Facebook and Tesla Motors, along with a number of biotechnology and cloud-computing stocks, have been pummeled in the last month. Facebook Inc, for example, has fallen nearly 22 percent from an intraday record reached less than a month ago.
*S&P 500 rises in Q1 for its fifth straight quarterly gain. NEW YORK, March 31- U.S. stocks rose on Monday, with the S&P 500 ending both March and the first quarter of 2014 with moderate gains, after Federal Reserve Chair Janet Yellen relieved concerns about a rate hike coming earlier than expected.
Stocks wrapped up the session on a high note, with the Dow logging triple-digit gains, after Federal Reserve Chair Janet Yellen said there's still room for the central bank to help the economy. But major index ended relatively flat for the first quarter.
*S&P on track for fifth straight quarterly advance. NEW YORK, March 31- U.S. stocks rose on Monday, with the S&P 500 on track to end the first quarter of 2014 with slight gains, after Federal Reserve Chair Janet Yellen calmed concerns about a rate hike coming earlier than expected. Micron Tech climbed 7.2 percent to $23.48 while Oracle Corp added 3.6 percent to $40.98.